Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Kivu Bioscience Inc.
Astellas Pharma Inc
Anova Innovation Limited
M.D. Anderson Cancer Center
University of California, San Francisco
M.D. Anderson Cancer Center
Institut du Cancer de Montpellier - Val d'Aurelle
IRCCS San Raffaele
M.D. Anderson Cancer Center
Cedars-Sinai Medical Center
M.D. Anderson Cancer Center
Evopoint Biosciences Inc.
Washington University School of Medicine
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Kestrel Therapeutics, Inc.
BigHat Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Boehringer Ingelheim
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Thomas Jefferson University
Montefiore Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cancer Trials Ireland
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
City of Hope Medical Center
Nammi Therapeutics Inc
National Cancer Institute (NCI)
Bristol-Myers Squibb
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
Beijing Biotech
AstraZeneca
Taiho Oncology, Inc.
Jazz Pharmaceuticals